Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization

Clinical Proteomics

Research

Ondrej Vit¹  Jiri Petrak¹  Igor Hartmann²  Zdenek Musil³  Pavel Talacko⁴  Karel Pacak⁵ 

[1]BIOCEV, First Faculty of Medicine, Charles University, 25250, Vestec, Czech Republic

[2]Department of Urology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900, Olomouc, Czech Republic

[3]Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, 12800, Prague, Czech Republic

[4]Proteomics Core Facility, Faculty of Science, BIOCEV, Charles University, 25250, Vestec, Czech Republic

[5]Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 20892, Bethesda, MD, USA

关键词: Pheochromocytoma;    Paraganglioma;    Neuroendocrine tumors;    Integral membrane proteins;    Membrane proteomics;    Drug targets;    Tumor imaging;    Therapy;   

DOI  :  10.1186/s12014-023-09428-7

 received in 2023-03-02, accepted in 2023-08-21,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors. New drug targets and proteins that would assist sensitive PPGL imagining could improve therapy and quality of life of patients with PPGL, namely those with recurrent or metastatic disease. Using a combined proteomic strategy, we looked for such clinically relevant targets among integral membrane proteins (IMPs) upregulated on the surface of tumor cells and non-membrane druggable enzymes in PPGL.MethodsWe conducted a detailed proteomic analysis of 22 well-characterized human PPGL samples and normal chromaffin tissue from adrenal medulla. A standard quantitative proteomic analysis of tumor lysate, which provides information largely on non-membrane proteins, was accompanied by specific membrane proteome-aimed methods, namely glycopeptide enrichment using lectin-affinity, glycopeptide capture by hydrazide chemistry, and enrichment of membrane-embedded hydrophobic transmembrane segments.ResultsThe study identified 67 cell surface integral membrane proteins strongly upregulated in PPGL compared to control chromaffin tissue. We prioritized the proteins based on their already documented direct role in cancer cell growth or progression. Increased expression of the seven most promising drug targets (CD146, CD171, ANO1, CD39, ATP8A1, ACE and SLC7A1) were confirmed using specific antibodies. Our experimental strategy also provided expression data for soluble proteins. Among the druggable non-membrane enzymes upregulated in PPGL, we identified three potential drug targets (SHMT2, ARG2 and autotaxin) and verified their upregulated expression.ConclusionsApplication of a combined proteomic strategy recently presented as “Pitchfork” enabled quantitative analysis of both, membrane and non-membrane proteome, and resulted in identification of 10 potential drug targets in human PPGL. Seven membrane proteins localized on the cell surface and three non-membrane druggable enzymes proteins were identified and verified as significantly upregulated in PPGL. All the proteins have been previously shown to be upregulated in several human cancers, and play direct role in cancer progression. Marked upregulation of these proteins along with their localization and established direct roles in tumor progression make these molecules promising candidates as drug targets or proteins for sensitive PPGL imaging.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

13690_2023_1170_Article_IEq9.gif

13690_2023_1170_Article_IEq124.gif

Fig. 7

Fig. 3

Fig. 2

Fig. 1

Fig. 2